Teicher, Martin H. http://orcid.org/0000-0002-6036-0177
Gordon, Jeoffry B. http://orcid.org/0000-0003-3901-6555
Nemeroff, Charles B. http://orcid.org/0000-0001-7867-1160
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (MH-117293, AA-024933, HD-079484, DA-017846)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
ANS Foundation
Article History
Received: 22 February 2021
Revised: 20 May 2021
Accepted: 15 October 2021
First Online: 4 November 2021
Competing interests
: MHT has created rating scales to retrospectively assess type and timing of exposure to CM [CitationRef removed] but there is no financial conflict as he has placed these scales into the public domain. MHT has also received research or consulting fees (last 12 months) from the NIH, Interactive Metronome™, Brain Balance Centers™, the ANS Foundation, and MindLight™. MHT is on the Scientific Advisory Board for the Juvenile Bipolar Research Foundation and member of the Board of Children, Youth and Families at the National Academies of Sciences, Engineering and Medicine and a member of the Board of Directors of the Trauma Research Foundation and the Kahn Family Foundation. MHT has been awarded 19 US Patents, none of which are relevant to this article. CBN has received grant support from the NIH. During the last 12 months, he has consulted to ANeuroTech (division of Anima BV), Signant Health, Sunovion Pharmaceuticals, Inc., Janssen Research & Development LLC, Magstim, Inc., Navitor Pharmaceuticals, Inc., Intra-Cellular Therapies, Inc., EMA Wellness, Acadia Pharmaceuticals, Axsome, Sage, BioXcel Therapeutics, Silo Pharma, XW Pharma, Neuritek, Engrail Therapeutics, and Corcept Therapeutics Pharmaceuticals Company. CBN is a stockholder in Xhale, Seattle Genetics, Antares, BI Gen Holdings, Inc., Corcept Therapeutics Pharmaceuticals Company, and EMA Wellness; he is on the Scientific Advisory Board for ANeuroTech (division of Anima BV), Brain and Behavior Research Foundation (BBRF), Anxiety and Depression Association of America (ADAA), Skyland Trail, Signant Health, Laureate Institute for Brain Research (LIBR), Inc., Magnolia CNS; and he is on the Board of Directors for Gratitude America, ADAA, and Xhale Smart, Inc. CBN holds two patents: Method and devices for transdermal delivery of lithium (US 6,375,990B1) and Method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2). He is not a part of any Speakers Bureau. JBG has no potential conflicts of interest to disclose.
Free to read: This content has been made available to all.